Emerging Science (Late-Breaker Equivalent)
Abstract To Be Presented At 5:30PM
Local Time Highlights Phase 2 PARADIGM Outcomes
CAMBRIDGE, Mass., April 12,
2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
(Nasdaq: NRSN) ("NeuroSense"), a company developing novel
treatments for severe neurodegenerative diseases, announces
lead author Merit Cudkowicz, Chair of Neurology at Massachusetts
General Hospital, and Julieanne Dorn Professor of Neurology at
Harvard Medical School, will be
presenting data from the PARADIGM Phase 2 study of PrimeC during an
Emerging Science session (equivalent to Late Breaker) at the
American Academy of Neurology Annual Meeting.
The presentation, titled, 'PrimeC, An Oral Candidate for
Amyotrophic Lateral Sclerosis, Meets Primary and Secondary
Endpoints in the Phase 2b PARADIGM
Trial.' Dr. Cudkowicz's presentation will be held on April 16, 2024 at 5:30PM local time. The meeting is being held
April 13-18 at the Colorado Convention Center in Denver, Colorado.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding PrimeC as a potential treatment
for people with ALS, the timing for release of additional results
from PARADIGM clinical trial, the cash runway of the Company, the
timing of a Phase 2 trial for Alzheimer's disease and patient
enrollment regarding a Phase 3 pivotal ALS trial of PrimeC.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
The future events and trends may not occur and actual results could
differ materially and adversely from those anticipated or implied
in the forward looking statements. These risks include unexpected
R&D costs or operating expenses, a delay in the reporting of
additional results from PARADIGM clinical trial, the timing of
expected regulatory and business milestones, risks associated with
meeting with the FDA to determine the best path forward following
the results from PARADIGM clinical trial, including a delay in any
such meeting, a delay in patient enrollment for a Phase 2 trial for
Alzheimer's disease; the potential for PrimeC to safely and
effectively target AD; preclinical and clinical data for PrimeC;
the uncertainty regarding outcomes and the timing of current and
future clinical trials; timing for reporting data; the development
and commercial potential of any product candidates of the company;
and other risks and uncertainties set forth in NeuroSense's filings
with the Securities and Exchange Commission (SEC). You should not
rely on these statements as representing our views in the future.
More information about the risks and uncertainties affecting the
Company is contained under the heading "Risk Factors" in the Annual
Report on Form 20-F filed with the Securities and Exchange
Commission on April 4, 2024.
Forward-looking statements contained in this announcement are made
as of this date, and NeuroSense Therapeutics Ltd. undertakes no
duty to update such information except as required under applicable
law.
Logo :
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-to-present-paradigm-data-at-the-american-academy-of-neurology-annual-meeting-april-16-2024-302115365.html
SOURCE NeuroSense